Supplementary Figure S5 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer

Surendra Nayak; John D. Norris; Massimo Ammirante; Emily Rychak; Suzanne E. Wardell; Debbie Liao; Brandon Toyama; Raju Kandimalla; Andy Christoforou; Toshiya Tsuji; Ken Liu; Minerva Tran; Joseph Meiring; Samantha Reiss; Joseph R. Piccotti; Joshua M. Baughman; Celia Fontanillo; Marwa Khater; Deborah S. Mortensen; Brian E. Cathers; Neil Bence; Daniel W. Pierce; Veronique Plantevin-Krenitsky; Dana E. Rathkopf; Joshua D. Hansen; Lawrence G. Hamann; Rama Krishna Narla; Vivek K. Arora; Donald Patrick McDonnell; Mark Rolfe; Shuichan Xu

doi:10.1158/1078-0432.31006849

Supplementary Figure S5 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer

2026 Open access

Read full text

Authors: Surendra Nayak, John D. Norris, Massimo Ammirante, Emily Rychak, Suzanne E. Wardell, Debbie Liao, Brandon Toyama, Raju Kandimalla, Andy Christoforou, Toshiya Tsuji, Ken Liu, Minerva Tran

+19 more

Joseph Meiring, Samantha Reiss, Joseph R. Piccotti, Joshua M. Baughman, Celia Fontanillo, Marwa Khater, Deborah S. Mortensen, Brian E. Cathers, Neil Bence, Daniel W. Pierce, Veronique Plantevin-Krenitsky, Dana E. Rathkopf, Joshua D. Hansen, Lawrence G. Hamann, Rama Krishna Narla, Vivek K. Arora, Donald Patrick McDonnell, Mark Rolfe, Shuichan Xu

DOI: 10.1158/1078-0432.31006849

Cited by: 0

Abstract

BMS-986365 overcomes resistance to ARPIs due to an adaptative mechanism in vitro.

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Estrogen and related hormone effects

Publication details

Publication date: 6 January 2026